ClinicalTrials.gg
CompletedNCT04706793Updated Oct 16, 2023Results posted

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

A Phase 3 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 38 sites in Japan. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
10th of 12
42 · median 195
Started
2020
with 1 other
Phase 3
5 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
6 of 12
Pfizer

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 10th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment in adult Japanese participants with moderately to severely active ulcerative colitis (UC). This study is an extension of study APD334-302 (NCT03996369). Participants will continue with the same blinded treatment assigned in Study APD334-302 for a total treatment duration of 52 weeks (12 weeks in Study APD334-302 plus 40 weeks in Study APD334-308).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
  • Etrasimod
  • APD334
  • UC
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with moderately to severely active ulcerative colitis (UC) are eligible to enroll into this study if they fulfill all of the following:

  • Must have completed the Week 12 visit of Study APD334-302
  • Ability to provide written or assent (parent or legal guardian must provide consent for a participant \< 20 years of age or as required per local regulations who has assented to participate in the study) and to be compliant with the schedule of protocol assessments. Enrollment of participants \< 20 years should be conducted only if acceptable according to local laws and regulations.
  • Both men and women subjects agree to use a highly effective method of if the possibility of conception exists

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following exclusion criteria will not be eligible for enrollment into the study:

  • If the Investigator considers the participant to be unsuitable for any reason to participate in the study
  • Participants requiring partial or total colectomy during the APD334-302 study
  • Participants requiring treatment with prohibited concomitant medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Etrasimod 2 mg

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308

    Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: Week 40 of APD334-308

Secondary outcomes

  1. Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308

    Endoscopic improvement was defined as an ES \<=1 (excluding friability) at Week 40 of APD334-308 compared with Week 12 of APD334-302. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.

    Time frame: Week 40 of APD334-308

  2. Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308

    Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

    Time frame: Week 40 of APD334-308

  3. Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308

    Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.

    Time frame: Week 40 of APD334-308

  4. Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry

    Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: Week 40 of APD334-308

  5. Percentage of Participants Achieving Sustained Clinical Remission

    Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease. A subject with sustained clinical remission is defined as someone who achieved clinical remission at both Week 12 of APD334-302 and Week 40 of APD334-308.

    Time frame: Week 40 of APD334-308

07

Results

Posted Oct 16, 2023

Participant flow

Treatment
Participant flow — Treatment
MilestonePlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Started1428
Completed418
Not completed1010
Withdrew: Disease worsening1010
Follow-up
Participant flow — Follow-up
MilestonePlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Started1428
Completed418
Not completed1010
Withdrew: Lack of efficacy10
Withdrew: Disease worsening810
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308

Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
Week 40 of APD334-308
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308
Percentage of participantsPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-3087.125.0
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: Etrasimod 2 mg · Risk difference (rd): 17.86 · 95% CI -3.10 to 38.82
SecondaryPercentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308

Endoscopic improvement was defined as an ES \<=1 (excluding friability) at Week 40 of APD334-308 compared with Week 12 of APD334-302. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.

Time frame:
Week 40 of APD334-308
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308
Percentage of participantsPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-3087.135.7
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: Etrasimod 2 mg · Risk difference (rd): 28.57 · 95% CI 6.28 to 50.86
SecondaryPercentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308

Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

Time frame:
Week 40 of APD334-308
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308
Percentage of participantsPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-3087.139.3
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: Etrasimod 2 mg · Risk difference (rd): 32.14 · 95% CI 9.58 to 54.71
SecondaryPercentage of Participants With Mucosal Healing at Week 40 of Study APD334-308

Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.

Time frame:
Week 40 of APD334-308
Reported as:
Number · Percentage of participants
Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308
Percentage of participantsPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-3087.128.6
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: Etrasimod 2 mg · Risk difference (rd): 21.43 · 95% CI -0.07 to 42.92
SecondaryPercentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry

Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
Week 40 of APD334-308
Reported as:
Number · Percentage of participants
Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry
Percentage of participantsPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry7.125.0
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: Etrasimod 2 mg · Risk difference (rd): 17.86 · 95% CI -3.10 to 38.82
SecondaryPercentage of Participants Achieving Sustained Clinical Remission

Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease. A subject with sustained clinical remission is defined as someone who achieved clinical remission at both Week 12 of APD334-302 and Week 40 of APD334-308.

Time frame:
Week 40 of APD334-308
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Clinical Remission
Percentage of participantsPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Percentage of Participants Achieving Sustained Clinical Remission07.1
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: Etrasimod 2 mg · Risk difference (rd): 7.14 · 95% CI -2.40 to 16.68

Adverse events

Collected over All-cause mortality, non-serious treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were collected during the 40-week continuous treatment period, followed by a 4-week follow-up period up to Week 44 of C5041013 (APD334-308).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Comparator: Placebo0/14 (0%)1/14 (7.1%)8/14 (57.1%)
Experimental: Etrasimod 2 mg0/28 (0%)1/28 (3.6%)16/28 (57.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
Colitis ulcerativeGastrointestinal disorders1/140/28
COVID-19Infections and infestations0/141/28
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo Comparator: PlaceboExperimental: Etrasimod 2 mg
PyrexiaGeneral disorders2/143/28
HeadacheNervous system disorders2/144/28
MalaiseGeneral disorders0/143/28
Colitis ulcerativeGastrointestinal disorders1/142/28
StomatitisGastrointestinal disorders1/140/28
Vaccination site painGeneral disorders0/142/28
Infected dermal cystInfections and infestations1/140/28
SinusitisInfections and infestations1/140/28
TonsillitisInfections and infestations1/140/28
Cervicobrachial syndromeNervous system disorders1/140/28

Baseline characteristics

Full Analysis Set: All randomized participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Placebo Comparator: PlaceboExperimental: Etrasimod 2 mgTotal
Mean44.2 ± 14.1243.9 ± 14.2944.0 ± 14.06
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Comparator: PlaceboExperimental: Etrasimod 2 mgTotal
Female71017
Male71825
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Comparator: PlaceboExperimental: Etrasimod 2 mgTotal
Hispanic or Latino000
Not Hispanic or Latino142842
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Comparator: PlaceboExperimental: Etrasimod 2 mgTotal
American Indian or Alaska Native000
Asian142842
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

38 sites
  • Kojunkai Daido Clinic
    Nagoya-shi, Aichi-ken 457-8511, Japan
  • Kojunkai Daido Hospital
    Nagoya-shi, Aichi-ken 457-8511, Japan
  • Nagoya City University Hospital
    Nagoya-shi, Aichi 467-8602, Japan
  • Toyohashi Municipal Hospital
    Toyohashi-shi, Aichi 441-8570, Japan
  • Tsujinaka Hospital Kashiwanoha
    Kashiwa-shi, Chiba 277-0871, Japan
  • Ishii Eye Clinic
    Nagareyama-shi, Chiba 270-0116, Japan
  • Fukuoka University Hospital
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • Takimoto Eye Clinic(OCT)
    Kasuga-shi, Fukuoka 816-0863, Japan
  • Fakuoka Tokushukai Hospital
    Kasuga-shi, Fukuoka 816-0864, Japan
  • Gifu University Hospital
    Gifu-shi, Gifu-ken 501-1194, Japan
  • SUBARU Health Insurance Society Ota Memorial Hospital
    Ota-shi, Gunma 373-8585, Japan
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima 734-8551, Japan
  • Asahikawa City Hospital
    Asahikawa-shi, Hokkaido 070-8610, Japan
  • NHO Mito Medical Center
    Higashiibaraki-gun, Ibaraki 311-3193, Japan
  • Matsumoto Eye Clinic
    Toride-shi, Ibaraki 302-0014, Japan
  • NHO Kanazawa Medical Center
    Kanazawa-shi, Ishikawa 920-8650, Japan
  • Takamatsu Red Cross Hospital
    Takamatsu-shi, Kagawa 760-0017, Japan
  • Kagawa Prefectural Central Hospital
    Takamatsu-shi, Kagawa 760-8557, Japan
  • JA- Kagoshima Koseiren Hospital (PET/DLCO)
    Kagoshima-shi, Kagoshima 890-0062, Japan
  • Kagoshima Kouseiren Hospital
    Kagoshima-shi, Kagoshima 890-0062, Japan
  • Clinical Pathology Laboratory (Diagnostick center)
    Kagoshima-shi, Kagoshima 892-0813, Japan
  • Jiaikai Idzuro Imamura Hospital
    Kagoshima-shi, Kagoshima 892-0824, Japan
  • Sameshima Eye Clinic (OCT)
    Kagoshima-shi, Kagoshima 892-0825, Japan
  • Sameshima Hospital
    Kagoshima-shi, Kagoshima 892-0846, Japan
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto-shi, Kumamoto 861-8520, Japan
  • National Hospital Organization Kyoto Medical Center
    Kyoto-shi, Kyoto 612-8555, Japan
  • Mie University Hospital
    Tsu-shi, MIE 514-8507, Japan
  • Mie Prefectural General Medical Center
    Yokkaichi-shi, MIE 510-8561, Japan
  • JOHAS Tohoku Rokai Hospital
    Sendai-shi, Miyagi 981-8563, Japan
  • JOHAS Tohoku Rosai Hospital
    Sendai-shi, Miyagi 981-8563, Japan
  • Sendai City Hospital
    Sendai-shi, Miyagi 982-8502, Japan
  • Japan Community Health care Organization Osaka Hospital
    Osaka-shi, Osaka 553-0003, Japan
  • Saga University Hospital
    Saga-shi, Saga 849-8501, Japan
  • St. Luke's International Hospital
    Chuo-ku, Tokyo 104-8560, Japan
  • Showa General Hospital
    Kodaira-shi, Tokyo 187-8510, Japan
  • Kitasato University Kitasato Institute Hospital
    Minato-ku, Tokyo 108-8642, Japan
  • JCHO Tokyo Yamate Medical Center
    Shinjuku-ku, Tokyo 169-0073, Japan
  • Wakayama Medical University Hospital
    Wakayama-shi, Wakayama 641-8510, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Aug 2022, 19 months.

Results were first posted in Oct 2023, 1 year 2 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 19 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 13, 2021
StartActual
Dec 25, 2020
Primary completionActual
Aug 3, 2022
CompletionActual
Aug 3, 2022
Results first posted
Oct 16, 2023
Last update
Oct 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04706793
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Dec 25, 2020
Primary completion
Aug 3, 2022
Completion
Aug 3, 2022
Results posted
Oct 16, 2023
Last update
Oct 16, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion